Curated News
By: NewsRamp Editorial Staff
October 30, 2026
Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial
TLDR
- Quantum BioPharma gains a CRO partner in Thermo Fisher for its Lucid-MS Phase 2 trial, advancing a first-in-class myelin-protection approach to progressive MS.
- Lucid-MS inhibits PAD2 to protect myelin, and the randomized, double-blind, placebo-controlled Phase 2 trial will assess safety, tolerability, and efficacy via clinical and radiological measures.
- Quantum BioPharma's Lucid-MS aims to protect myelin and potentially improve lives for people with progressive multiple sclerosis by targeting a root cause rather than only the immune system.
- Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation, and Quantum BioPharma also invented UNBUZZD and retains a royalty stake in its spun-out wellness business.
Impact - Why it Matters
This news matters because it signals that Quantum BioPharma is moving a novel myelin-protective approach for progressive MS into Phase 2 testing with an experienced CRO. If Lucid-MS succeeds, it could offer a treatment strategy that differs from existing immune-focused therapies by directly targeting myelin damage—a root mechanism of MS. For patients with progressive forms of the disease, which have limited treatment options, this represents a potentially meaningful new direction. For investors, the Thermo Fisher agreement reduces execution risk around trial start-up and provides a credible partner for a central nervous system study. However, the program remains early-stage and investigational, with enrollment details still pending, so the impact will depend on future clinical results and timelines.
Summary
Quantum BioPharma (NASDAQ: QNTM) has taken a significant step toward advancing its investigational multiple sclerosis therapy, Lucid-MS, by signing a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business. The agreement, which follows U.S. Food and Drug Administration clearance of the Investigational New Drug application in August 2026, enlists a contract research organization with deep experience in central nervous system and MS studies to help launch the Phase 2 clinical trial. Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin—the protective coating around nerve fibers—by inhibiting PAD2, an enzyme implicated in myelin damage. The randomized, double-blind, placebo-controlled trial will assess the candidate’s safety, tolerability and efficacy using both clinical and radiological measures.
Although preclinical research and Phase 1 testing have yielded encouraging findings, Lucid-MS remains investigational, and Quantum BioPharma has not yet announced enrollment dates or trial sites. The company, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on developing this patented new chemical entity, which has been shown to prevent and reverse myelin degradation in preclinical models. Quantum also invented UNBUZZD(TM) and retains a 19.48% ownership stake in Unbuzzd Wellness Inc., along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. For more information, visit www.QuantumBioPharma.com.
The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions to help companies reach investors and the public. The latest updates on QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial
